Zobrazeno 1 - 10
of 206
pro vyhledávání: '"Abhinav Deol"'
Autor:
Nikhil Munshi, Tom Martin, Saad Z Usmani, Jesus Berdeja, Andrzej Jakubowiak, Mounzer Agha, Adam D Cohen, Abhinav Deol, Myo Htut, Alexander Lesokhin, Yi Lin, Elizabeth O’donnell, Carolyn C Jackson, Tzu-Min Yeh, Arnob Banerjee, Enrique Zudaire, Deepu Madduri, Christopher Delcorral, Lida Pacaud, Sundar Jagannath
Publikováno v:
HemaSphere, Vol 7, p e6102468 (2023)
Externí odkaz:
https://doaj.org/article/0953a89f5cd849b38cfb3f30eba6c672
Autor:
Lori Leslie, Michael Tees, Ian W. Flinn, Tulio Rodriguez, John H. Baird, Abhinav Deol, Monica Mead, Carlos Bachier, Aaron P. Rapoport, Brian Mcclune, Daanish Hoda, Miguel-Angel Perales, Yan Zheng, Simone Filosto, Madison Davis, Harry Miao, Jenny J. Kim, Olalekan O. Oluwole
Publikováno v:
HemaSphere, Vol 7, p e50042ff (2023)
Externí odkaz:
https://doaj.org/article/cf51f2eb81ef4620b604ac78295b8d69
Autor:
Michael Simon, Qin Liu, Lawrence Flaherty, Lawrence G. Lum, Archana Thakur, Abhinav Deol, Kristie Fields, Dana Schalk, Zaid Al-Kadhimi, Vidya Kondadasula, Elyse Tomashewski, Patricia Steele, Melissa Giroux
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Metastatic human epidermal growth receptor II (HER2) negative breast cancer remains incurable. Our phase I study showed that anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) may be effective against HER2-tumors
Externí odkaz:
https://doaj.org/article/57a46f642d4b4f41b29378a6a4fcd193
Autor:
Lawrence G. Lum, Archana Thakur, Minsig Choi, Abhinav Deol, Vidya Kondadasula, Dana Schalk, Kristie Fields, Melissa Dufrense, Philip Philip, Gregory Dyson, Hussein D. Aon, Anthony F. Shields
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Purpose This was a phase I/II adoptive T cell trial in 7 locally advanced and metastatic pancreatic cancer patients using 3–8 infusions of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATs) to determine safety, the maximum tole
Externí odkaz:
https://doaj.org/article/37883bb3779b4c5ca386040a5d50fb03
Publikováno v:
Transplant Research and Risk Management, Vol 2011, Iss default, Pp 31-44 (2011)
Abhinav Deol, Voravit Ratanatharathorn, Joseph P UbertiDepartment of Oncology, Blood and Marrow Stem Cell Transplant Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USAAbstract: Acute graft-vers
Externí odkaz:
https://doaj.org/article/6f43355e57e14aff81e4d49b9b376330
Autor:
Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier L. Munoz, Saurabh Dahiya, Amer M. Beitinjaneh, Miriam T. Jacobs, Joseph P. Mcguirk, Julie M. Vose, Andre Goy, Charalambos Andreadis, Brian T. Hill, Kathleen A. Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael L. Wang, Michael D. Jain
Publikováno v:
Journal of Clinical Oncology. 41:2594-2606
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell lymphoma (MCL). This therapy was approved on the basis of the single-arm phase II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1ebedb9cdef4e30b7e8b0e20978feb3
https://doi.org/10.1200/jco.22.01797
https://doi.org/10.1200/jco.22.01797
Autor:
Dipenkumar Modi, Samer Alkassis, Seongho Kim, Andrew Kin, Abhinav Deol, Lois Ayash, Voravit Ratanatharathorn, Joseph P. Uberti
Publikováno v:
Leukemia & Lymphoma. :1-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c431ccf3fef246b98741b2824cd9e78f
https://doi.org/10.1080/10428194.2023.2206181
https://doi.org/10.1080/10428194.2023.2206181
Autor:
Thomas Martin, Saad Z. Usmani, Jesus G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander Lesokhin, Nikhil C. Munshi, Elizabeth O'Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu-Min Yeh, Arnob Banerjee, Alicia Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath
Publikováno v:
Journal of Clinical Oncology. 41:1265-1274
PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months. He
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d3e2bf5d05bd705a2910316a7fe64d2
https://doi.org/10.1200/jco.22.00842
https://doi.org/10.1200/jco.22.00842
Autor:
Miriam T. Jacobs, Michael D. Jain, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph McGuirk, Abhinav Deol, Alison Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier Munoz, Julio C. Chavez, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Armin Ghobadi, Frederick L. Locke
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:753-759
The majority of patients with large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, develop cytokine release syndrome (CRS). Whether the lack of development of CRS with axi-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4df67cd9619f066605f7a15d48450a1
https://doi.org/10.1016/j.clml.2022.05.004
https://doi.org/10.1016/j.clml.2022.05.004
Autor:
Michael Slade, Thomas G. Martin, Nitya Nathwani, Mark A. Fiala, Michael P. Rettig, Feng Gao, Abhinav Deol, Francis K. Buadi, Jonathan L. Kaufman, Craig C. Hofmeister, Tara K. Gregory, Jesus Berdeja, Ajai Chari, Ashley Rosko, Ravi Vij
Publikováno v:
Leukemia. 36:2917-2921
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96e46dd53c29a33c25c2d32505f5cff6
https://doi.org/10.1038/s41375-022-01691-1
https://doi.org/10.1038/s41375-022-01691-1